Last updated on July 2019

Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies


Brief description of study

The primary objective of the study is to assess the safety, tolerability, and Pharmacokinetics (PK) of REGN2810 in Japanese patients with advanced malignancies. The secondary objective of the study is to assess the immunogenicity of REGN2810.

Clinical Study Identifier: NCT03233139

Find a site near you

Start Over